Nusano
Assembly Line
Nusano Announces Series C Financing of Over $115M to Commercialize Radioisotopes
Nusano, Inc., a physics company transforming the production of radioisotopes, announced a Series C financing round with funding commitments of over $115 million in total proceeds. The financing will support the company’s initial product launches of non-carrier-added lutetium-177 (n.c.a. Lu-177) and actinium-225 (Ac-225).
The round was led by The Wasatch Group, with additional participation by S32. Previous investors in Nusano include Verily and the American Cancer Society’s BrightEdge.
Nusano is working to stabilize supply chains and enable innovation by bringing new sources of radioisotopes to medical and industrial markets. In 2025, the company will launch two breakthrough technologies poised to transform radioisotope supply availability: a proprietary separation process for high-volume n.c.a. Lu-177 production, and a first-of-its-kind radioisotope production platform.